Pediatricians Urge DEA to Reclassify Medical Marijuana to Boost Research
Specifically, the AAP wants marijuana to be removed from the DEAs Schedule 1 listing for controlled substances, which are not considered to have any currently accepted medical use in the U.S., a lack of accepted safety for under medical supervision and a high potential for abuse. Other drugs in this category include heroin, acid and ecstasy.
Instead, the medical society wants marijuana downgraded to the list of Schedule 2 drugs, which are considered to have a high potential for abuse which may lead to severe psychological or physical dependence. These include various widely prescribed narcotics, such as oxycodone and fentanyl, as well as morphine and codeine, which are used for medical purposes.
A Schedule 1 listing means theres no medical use or helpful indications, but we know thats not true because there has been limited evidence showing [marijuana] may be helpful for certain conditions in adults, says Seth Ammerman, a clinical professor in pediatrics at Stanford University and a member of the AAP national committee on substance abuse, who co-authored the new policy statement.
By placing this on Schedule 2, it would allow the FDA to be involved [in pediatric research] as the agency is in any study. Unless scheduling changes, this wont happen. And there could be therapeutic benefits. The AAP is not opposed to medical marijuana, per se, but we feel its important that this be explored within the [framework of the] FDA process, where you have standardization.
http://www.wsj.com/articles/BL-270B-1364